Recent Finacing
Recent Raise
Euclises Pharmaceuticals develops third-generation COX-2 inhibitors (Euclicoxib platform) for oncology, advancing lead candidate ECP-1014 through IND-enabling preclinical studies with a China development partner (GIBH).
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
